C. Boyd Clarke Named Chairman of Aviron Board of Directors
MOUNTAIN VIEW, Calif., Jan. 8 /PRNewswire/ --
Aviron (Nasdaq: AVIR) today announced that it received a $10 million payment
from American Home Products Corporation (NYSE: AHP) to support commercial
manufacturing and inventory build-up of FluMist(TM) for a potential product
launch during the 2001-2002 influenza season. This payment is an advance for
payments AHP owes Aviron under the companies' global collaboration agreement
for FluMist(TM).
The U.S. Food and Drug Administration (FDA) is currently reviewing a
Biologics License Application for FluMist(TM) seeking marketing approval for
the prevention of influenza in healthy children and healthy adults.
"We are delighted that our partners at American Home Products have
provided their financial support for FluMist(TM) to assist in the commercial
production already underway. These manufacturing activities are essential for
us to execute a product launch during the 2001-2002 influenza season if we
receive marketing clearance from the FDA," said C. Boyd Clarke, Aviron
president and chief executive officer.
Aviron also announced today that Mr. Clarke has been elected chairman of
the board of directors. He succeeds J. Leighton Read, M.D., Aviron's founder,
who will remain on Aviron's board of directors.
"Boyd Clarke's election to chair Aviron's board reflects our appreciation
for the progress the company has made under his first year of leadership and
the confidence we have in his ability to continue Aviron's transition into a
commercial stage company," Read said.
Aviron is a biopharmaceutical company based in Mountain View, California,
focused on the prevention of disease through innovative vaccine technology.
Actual results may differ materially from the forward-looking statements
contained in this release. Factors that could cause actual results to differ
include, but are not limited to, the assessment by regulatory agencies that
the company's license applications for its nasal influenza vaccine are
incomplete or inadequate to approve the product for marketing to one or more
target populations. Additional information concerning factors that could
cause such a difference is contained in Aviron's SEC filings, including its
recent Registration Statements on Form S-3 and Annual Report on Form 10-K for
the year ended December 31, 1999.
To receive an index and copies of recent press releases, call Aviron's
News-On-Call toll-free fax service, 800-758-5804, extension 114000.
Additional information about the company can be located at
http://www.aviron.com .
SOURCE Aviron
 back to top
Related links:
http://www.aviron.com
Company News On-Call:
http://www.prnewswire.com/comp/114000.html or fax,
800-758-5804, ext. 114000
CONTACT:
media, John Bluth, 650-919-3716, or Asha
Jennings, 650-919-1429, both of Aviron; or Camela Stuby of
Fleishman-Hillard, 212-453-2000, for Aviron; or investors, John
Bluth, 650-919-3716, or Fred Kurland, 650-919-6666, or Asha
Jennings, 650-919-1429, all of Aviron
|
